Germany· DE-A57-47c0c4749abc6ddf

Lyovac-Cosmegen

A dactinomycin product containing dactinomycin, registered in Germany by Recordati Rare Diseases. The same ATC class is registered in 7 of our 19 countries.

ATC L01DA01

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedLyovac-CosmegenATCL01DA01REGISTER NO.DE-A57-47c0c4749abc6d…PACKS LISTED0CHECKEDSeptember 30, 2026

Where it is registered

Dactinomycin is registered in 7 of 19 countries.

Countries holding a registration under ATC L01DA01 (dactinomycin), each read from that country’s own register.

  • This record: Germany, from EMA Article 57 (European Union)
  • 4 of them publish a price we can compare per daily dose

Dactinomycin · ATC L01DA01

7 / 19 countries

  • Canada
  • Finlandprice
  • Franceprice
  • Germany
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

EMA Article 57 (European Union)
Active substance
Dactinomycin
Manufacturer
Recordati Rare Diseases
Country
Germany (DE)
ATC code
L01DA01
ATC class
Dactinomycin
Defined daily dose
0.32 mg, P
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

163 interactions on record for dactinomycin.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Dactinomycin · interactions on record

163 records

  • 30 severe
  • 83 moderate
  • 15 minor
  • 35 info

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dactinomycin in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dactinomycin products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • France · Cosmegen
  • Italy · Cosmegen

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e3c51590-7015-403f-a85b-e84f237ca211
GET /v1/drugs/e3c51590-7015-403f-a85b-e84f237ca211?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Intravenous Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Dactinomycin",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}

See everything about dactinomycin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.